592 related articles for article (PubMed ID: 33253920)
1. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
Rizk JG; Forthal DN; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Pfeiffer JP; Lewin JC
Drug Discov Today; 2021 Feb; 26(2):593-603. PubMed ID: 33253920
[TBL] [Abstract][Full Text] [Related]
2. Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.
Thomson K; Nachlis H
JAMA; 2020 Oct; 324(13):1282-1283. PubMed ID: 32870235
[No Abstract] [Full Text] [Related]
3. Recent advances in management of COVID-19: A review.
Mouffak S; Shubbar Q; Saleh E; El-Awady R
Biomed Pharmacother; 2021 Nov; 143():112107. PubMed ID: 34488083
[TBL] [Abstract][Full Text] [Related]
4. The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic.
Tran A; Witek TJ
Pharmaceut Med; 2021 Jul; 35(4):203-213. PubMed ID: 34453703
[TBL] [Abstract][Full Text] [Related]
5. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
6. Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.
Awadasseid A; Wu Y; Tanaka Y; Zhang W
Biomed Pharmacother; 2021 May; 137():111330. PubMed ID: 33550043
[TBL] [Abstract][Full Text] [Related]
7. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review.
Khani E; Khiali S; Entezari-Maleki T
J Clin Pharmacol; 2021 Apr; 61(4):429-460. PubMed ID: 33511638
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
Moirangthem DS; Surbala L
Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19.
Parums DV
Med Sci Monit; 2021 Aug; 27():e934393. PubMed ID: 34393218
[TBL] [Abstract][Full Text] [Related]
10. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.
Wolf J; Abzug MJ; Wattier RL; Sue PK; Vora SB; Zachariah P; Dulek DE; Waghmare A; Olivero R; Downes KJ; James SH; Pinninti SG; Yarbrough A; Aldrich ML; MacBrayne CE; Soma VL; Grapentine SP; Oliveira CR; Hayes M; Kimberlin DW; Jones SB; Bio LL; Morton TH; Hankins JS; Maron GM; Timberlake K; Young JL; Orscheln RC; Schwenk HT; Goldman DL; Groves HE; Huskins WC; Rajapakse NS; Lamb GS; Tribble AC; Lloyd EC; Hersh AL; Thorell EA; Ratner AJ; Chiotos K; Nakamura MM
J Pediatric Infect Dis Soc; 2021 May; 10(5):629-634. PubMed ID: 33388760
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
Parums DV
Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
[TBL] [Abstract][Full Text] [Related]
12. An EUA for bamlanivimab and etesevimab for COVID-19.
Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966
[No Abstract] [Full Text] [Related]
13. Remdesivir emergency approvals: a comparison of the U.S., Japanese, and EU systems.
Saint-Raymond A; Sato J; Kishioka Y; Teixeira T; Hasslboeck C; Kweder SL
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1095-1101. PubMed ID: 32909843
[TBL] [Abstract][Full Text] [Related]
14. An EUA for sotrovimab for treatment of COVID-19.
Med Lett Drugs Ther; 2021 Jun; 63(1627):97-xx98. PubMed ID: 34181630
[No Abstract] [Full Text] [Related]
15. A review of clinical efficacy data supporting emergency use authorization for COVID-19 therapeutics and lessons for future pandemics.
Yoo SH; Kim L; Lu M; Nagoshi K; Namchuk MN
Clin Transl Sci; 2022 Oct; 15(10):2279-2292. PubMed ID: 35929015
[TBL] [Abstract][Full Text] [Related]
16. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Atluri S; Manchikanti L; Hirsch JA
Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
[TBL] [Abstract][Full Text] [Related]
17. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 challenges and its therapeutics.
Rehman SU; Rehman SU; Yoo HH
Biomed Pharmacother; 2021 Oct; 142():112015. PubMed ID: 34388532
[TBL] [Abstract][Full Text] [Related]
19. An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19.
Kesselheim AS; Darrow JJ; Kulldorff M; Brown BL; Mitra-Majumdar M; Lee CC; Moneer O; Avorn J
Health Aff (Millwood); 2021 Jan; 40(1):25-32. PubMed ID: 33211535
[TBL] [Abstract][Full Text] [Related]
20. Casirivimab/Imdevimab: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
